TY - JOUR T1 - Estimating external exposure from patients after treatment with Cu-67 SARTATE. JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1624a LP - 1624a VL - 60 IS - supplement 1 AU - Colin Biggin AU - Ellen van Dam AU - Matthew Harris AU - Michelle Parker AU - Geoff Schembri Y1 - 2019/05/01 UR - http://jnm.snmjournals.org/content/60/supplement_1/1624a.abstract N2 - 1624aObjectives: After the administration of therapeutic radiopharmaceuticals, the activity retained within the patient can provide measurable radiation exposure to their family, friends and caregivers. Appropriate patient restrictions after administration, which in some cases can include patient isolation, are required to ensure that the exposure to others is minimised. Cu-67 SARTATE is in clinical development for a range of different cancers including meningioma, neuroblastoma and neuroendocrine tumours. Other Cu-67 based radiopharmaceuticals are also in development using different targeting moieties including Bombesin and PSMA and clinical trials will commence in 2019. Methods: A model has been created using published dose coefficients for Cu-67 and preclinical estimates of effective half-life of Cu-67 SARTATE in the patient. This was used to estimate external radiation exposure from patients over time during the clearance of the investigation product from the body. This allowed development of a series of patient restrictions and dose estimates to family, friends and the general public could be estimated based on the patient restrictions. Results: The external dose rate estimates were then verified by dose rate measurements during the first-in-human clinical of Cu-67 SARTATE in patient with meningioma based in Australia. Conclusions: Based on the current suggested patient restrictions, in the first few days after administration, dose estimate to friends, family and caregivers were below the generally accepted level of 1mSv to children and pregnant/nursing mother and the general public and 5mSv for primary caregivers. Furthermore, the results indicate that Cu-67 SARTATE can be given on an outpatient basis, which is in agreement with NUREG 1556, Vol 9, Rev 2 (Table U.1), which states 14GBq Cu-67 is the maximum activity where patients are still releasable. ER -